Ambit Biosciences Corp

AMBI

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to suspend trading in the two securities enumerated below (“Securities”) of Ambipar Emergency Response (the “Company”) from NYSE American. Symbol Description AMBI Ordinary Shares AMBIWS Warrants The Exchange previously announced on October 22, 2025 that the Company was no longer suitable for listing pursuant to Section 1003(c)(iii) of the NYSE America.

Shares of Ambipar Emergency Response (NYSE American: AMBI) dropped 31% to 77 cents on Thursday after trading resumed, following a two-day halt triggered by the company's bankruptcy filing earlier in the week. The stock fluctuated between a low of 48 cents — its 52-week low — and a high of 95 cents during intraday trading.

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the two securities enumerated below (“Securities”) of Ambipar Emergency Response (the “Company”) from NYSE American. Symbol Description AMBI Ordinary Shares AMBIWS Warrants NYSE Regulation has determined that the Company is no longer suitable for listing and will commence delisting proceedings pursuant to Section 1003.

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.

SÃO PAULO, July 10, 2025 /PRNewswire/ -- Ambipar Emergency Response (NYSE: AMBI; AMBIWS) (the "Company") announces that on June 23,2025, the Company filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the "2024 Annual Report") with the U.S. Securities and Exchange Commission (the "SEC"). The 2024 Annual Report and audited financial statements can be accessed by visiting either the SEC's website at www.sec.gov or the Company's website at https://ir-response.ambipar.com/.